タイトル:

出版社:

ISBN:

著者:

キーワード:

カテゴリー:

発行年:

～

検索条件をクリア

書籍詳細

未契約

書籍名	FDG-PETマニュアル検査と読影のコツ
出版社	インナービジョン
発行日	2004-06-07
著者	陣之内正史(編著) 吉田毅(著) 落合礼次(著) 田邉博昭(著)
ISBN	9784902131079
ページ数	262
版刷巻号	第3刷
分野	臨床医学：一般放射線/核医学
閲覧制限	未契約

最近のPET施設の増加の反面、FDG-PET検査に携わる核医学あるいは放射線科の専門医不足が問題となってくると思われる。また、FDG-PETの臨床に即したテキストが少なく、あっても画像が古いため、最新のPET画像を読影する際に参考にならないものが多い。本書は、これからPET診療に携わる人や比較的経験の浅い人を対象として、PET検査と読影のコツがつかめるように工夫したものである。

目次

表紙
閲覧
推薦の詞
P.2閲覧
推薦の詞
P.3閲覧
序
P.5閲覧
目次
P.6閲覧
第1章総論
P.11閲覧
- 1. 検査法のコツ
- 2. 読影法のコツ
- 3. 臨床的意義と限界
- 4. サービス面のコツ
- 5. PET検診のデータ
第2章各論
P.65閲覧
- 1. 脳
- 2. 頭頸部
- 3. 甲状腺
- 4. 肺
- 5. 縦隔
- 6. 乳腺
- 7. 肝, 胆道
- 8. 膵
- 9. 食道
- 10. 胃, 十二指腸
- 11. 大腸, 小腸
- 12. 泌尿器系
- 13. 副腎
- 14. 子宮
- 15. 卵巣
- 16. 骨・軟部組織
- 17. 悪性リンパ腫
- 18. 血液疾患
- 19. 悪性黒色腫
- 20. 原発不明癌
略語一覧
P.252閲覧
索引
P.253閲覧
著者紹介 / 施設紹介
P.261閲覧
奥付
閲覧

参考文献

推薦の詞

P.15 掲載の参考文献

1) Bar-Shalom, R., Valdivia, A. Y., Blaufox, M. D. : PET imaging in oncology. Semin. Nucl. Med., 30 (3) ; 150-185, 2000.
pubmed

2) Kubota, K. : From tumor biology to clinical Pet : A review of positron emission tomography (PET) in oncology. Ann. Nucl. Med., 15 (6) ; 471-486, 2001.
pubmed

3) Hustinx, R., Benard, F., Alavi, A. : Whole-body FDG-PET imaging in the management of patients with cancer. Semin. Nucl. Med., 32 (1) ; 35-46, 2002.
pubmed

4) Bomanji, J. B., Costa, D. C., Ell, P. J. : Clinical role of positron emission tomography in oncology. Lancet Oncol., 2 (3) ; 157-164, 2001.
pubmed

5) 佐々木雅之 : 腫瘍FDG-PETの臨床. 日本医学放射線学会雑誌, 61 ; 414-420, 2001.

6) 中本裕士 : 腫瘍PET-入門からPET/CTまで. 日本医学放射線学会雑誌, 63 ; 285-293, 2003.

7) 窪田和雄 : クリニカルPET-FDGの臨床応用 : FDG-PETの原理と評価法. 画像診断, 23 (10) ; 1118-1128, 2003.

8) Schulthess, G. K. : Clinical positron emission tomography (PET) : Correlation with morphological cross-sectional imaging. Lippincott Williams & Wilkins (Philadelphia), 2001.

9) 伊藤正敏, 遠藤啓吾, 越智宏暢, 他 : 臨床医のためのクリニカルPET. 先端医療技術研究所 (東京), 2001.

10) 鳥塚莞爾, 小西淳二, 増田康治, 他 : クリニカルPETハンドブック. 技術経済研究所 (東京), 2001.

11) 正津晃, 井出満, 安田聖栄, 他 : PETを中心とした成人病検診. 日本医事新報社 (東京), 2002.

12) Wahl, R. L., Henry, C. A., Ethier, S. P. : Serum glucose : Effects on tumor and normal tissue accumulation of 2- [F-18] -fluoro-2-deoxy-D-glucose in rodents with mammary carcinoma. Radiology, 183 ; 643-647, 1992.
pubmed

13) Lindholm, P., Minn, H., Leskinen-Kallio, S., et al. : Influence of the blood glucose concentration on FDG uptake in cancer : A PET study. J. Nucl. Med., 34 ; 1-6, 1993.

14) Zhuang, H. M., Cortes-Blanco, A., Pourdehnad, M., et al. : Do high glucose levels have differential effect on FDG uptake in inflammatory and malignant disorders? Nucl. Med. Commun., 22 (10) ; 1123-1128, 2001.
pubmed

15) Gorenberg, M., Hallett, W. A., O'Doherty, M. J. : Does diabetes affect [(18) F] FDG standardised uptake values in lung cancer? Eur. J. Nucl. Med. Mol. Imaging, 29 (10) ; 1324-1327, 2002.
pubmed

16) Leisure, G. P., Vesselle, H. J., Faulhaber, P. F., et al. : Technical improvements in fluorine-18-FDG PET imaging of the abdomen and pelvis. J. Nucl. Med. Technol., 25 ; 115-119, 1997.
pubmed

17) Miraldi, F., Vesselle, H., Faulhaber, P. F., et al. : Elimination of artifactual accumulation of FDG in PET imaging of colorectal cancer. Clin. Nucl. Med., 23 (1) ; 3-7, 1998.
pubmed

18) Moran, J. K., Lee, H. B., Blaufox, M. D. : Optimization of urinary FDG excretion during PET imaging. J. Nucl. Med., 40 ; 1352-1357, 1999.
pubmed

19) Hamblen, S. M., Lowe, V. J. : Clinical 18F-FDG oncology patient preparation techniques. J. Nucl. Med. Technol., 31 (1) ; 3-7 ; quiz 8-10, 2003.

20) 陣之内正史, 田邉博昭 : 厚地記念クリニックの現況と展望. 断層映像研究会雑誌, 30 (1) ; 6-15, 2003.
Medical*Online

21) Hustinx, R., Smith, R. J., Benard, F., et al. : Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography : A potential method to differentiate malignancy from inflammation and normal tissue in the head and neck. Eur. J. Nucl. Med., 26 (10) ; 1345-1348, 1999.
pubmed

22) Nakamoto, Y., Higashi, T., Sakahara, H., et al. : Delayed (18) F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas. Cancer, 89 ; 2547-2554, 2000.
pubmed

23) Zhuang, H., Pourdehnad, M., Lambright, E. S., et al. : Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J. Nucl. Med., 42 (9) ; 1412-1417, 2001.
pubmed

24) Kubota, K., Itoh, M., Ozaki, K., et al. : Advantage of delayed whole-body FDG-PET imaging for tumour detection. Eur. J. Nucl. Med., 28 ; 696-703, 2001.
pubmed

25) Matthies, A., Hickeson, M., Cuchiara, A., et al. : Dual time point 18F-FDG PET for the evaluation of pulmonary nodules. J. Nucl. Med., 43 ; 871-875, 2002.
pubmed

26) Riddell, C., Carson, R. E., Carrasquillo, J. A., et al. : Noise reduction in oncology FDG PET images by iterative reconstruction : A quantitative assessment. J. Nucl. Med., Sep 42 (9) ; 1316-1323, 2001.
pubmed

P.52 掲載の参考文献

27) Fujiwara, T., Miyake, M., Watanuki, S., et al. : Easy detection of tumor in oncologic whole-body PET by projection reconstruction images with maximum intensity projection algorithm. Ann. Nucl. Med., 13 (3) ; 199-203, 1999.
pubmed

28) Aquino, S. L., Asmuth, J. C., Alpert, N. M., et al. : Improved radiologic staging of lung cancer with 2- [18F] -fluoro-2-deoxy-D-glucose-positron emission tomography and computed tomography registration. J. Comput. Assist. Tomogr., Jul-Aug, 27 (4) ; 479-484, 2003.

29) Gordon, B. A., Flanagan, F. L., Dehdashti, F. : Whole-body positron emission tomography : Normal variations, pitfalls, and technical considerations. AJR Am. J. Roentgenol., 169 ; 1675-1680, 1997.
pubmed

30) Strauss, L. G. : Fluorine-18 deoxyglucose and falsepositive results : A major problem in the diagnostics of oncological patients. Eur. J. Nucl. Med., 23 (10) ; 1409-1415, 1996.

31) 加藤貴司, 塚本江利子, 杉並裕子, 他 : 全身FDG-PET検査における正常分布の検討. 核医学, 36 ; 971-977, 1999.
Medical*Online

32) Shreve, P. D., Anzai, Y., Wahl, R. L. : Pitfalls in oncologic diagnosis with FDG PET imaging : Physiologic and benign variants. Radiographics, 19 (1) ; 61-77, 1999.

33) 山口慶一郎, 鷺野谷利幸, 伊藤正敏 : クリニカルPET-FDGの臨床応用 : 正常画像と生理的変動. 画像診断, 23 (10) ; 1129-1141, 2003.

34) Kawabe, J., Okamura, T., Shakudo, M., et al. : Physiological FDG uptake in the palatine tonsils. Ann. Nucl. Med., 15 (3) ; 297-300, 2001.
pubmed

35) Kawabe, J., Okamura, T., Shakudo, M., et al. : Two cases of chronic tonsillitis studied by FDG-PET. Ann. Nucl. Med., 13 (4) ; 277-279, 1999.
pubmed

36) Horiuchi, M., Yasuda, S., Shohtsu, A., Ide, M. : Four cases of Warthin's tumor of the parotid gland detected with FDG PET. Ann. Nucl. Med., 12 (1) ; 47-50, 1998.
pubmed

37) Kostakoglu, L., Wong, J. C., Barrington, S. F., et al. : Speech-related visualization of laryngeal muscles with fluorine-18-FDG. J. Nucl. Med., 37 (11) ; 1771-1773, 1996.
pubmed

38) Kamel, E. M., Goerres, G. W., Burger, C., et al. : Recurrent laryngeal nerve palsy in patients with lung cancer : Detection with PET-CT image fusion : Report of six cases. Radiology, 24 (1) ; 153-156, 2002.

39) Wolf, G., Aigner, R. M., Schaffler, G., et al. : Pathology results in [18F] fluorodeoxyglucose positron emission tomography of the thyroid gland. Nucl. Med. Commun., 24 (12) ; 1225-1230, 2003.
pubmed

40) Yasuda, S., Shohtsu, A., Ide, M., et al. : Chronic thyroiditis : Diffuse uptake of FDG at PET. Radiology, 207 (3) ; 775-778, 1998.
pubmed

41) Schmid, D. T., Kneifel, S., Stoeckli, S. J., et al. : Increased 18F-FDG uptake mimicking thyroid cancer in a patient with Hashimoto's thyroiditis. Eur. Radiol., 13 (9) ; 2119-2121, 2003.

42) Nakahara, T., Fujii, H., Ide, M., Nishiumi, N., et al. : FDG uptake in the morphologically normal thymus : Comparison of FDG positron emission tomography and CT. Br. J. Radiol., 74 (885) ; 821-824, 2001.
pubmed

43) Hicks, R. J., Binns, D., Stabin, M. G. : Pattern of uptake and excretion of (18) F-FDG in the lactating breast. J. Nucl. Med., 42 (8) ; 1238-1242, 2001.

44) Alavi, A., Gupta, N., Alberini, J. L., et al. : Positron emission tomography imaging in nonmalignant thoracic disorders. Semin. Nucl. Med., 32 (4) ; 293-321, 2002.
pubmed

45) Yeung, H. W., Grewal, R. K., Gonen, M., et al. : Patterns of (18) F-FDG uptake in adipose tissue and muscle ; A potential source of false-positives for PET. J. Nucl. Med., 44 (11) ; 1789-1796, 2003.

46) Bakheet, S. M., Powe, J., Ezzat, A., et al. : F-18-FDG uptake in tuberculosis. Clin. Nucl. Med., 23 (11) ; 739-742, 1998.
pubmed

47) Goo, J. M, Im, J. G., Do, K. H., et al. : Pulmonary tuberculoma evaluated by means of FDG PET : Findings in 10 cases. Radiology, 216 (1) ; 117-121, 2000.
pubmed

48) Halter, G., Storck, M., Guhlmann, A., et al. : FDG positron emission tomography in the diagnosis of peripheral pulmonary focal lesions. Thorac. Cardiovasc. Surg., 48 (2) ; 97-101, 2000.
pubmed

49) Bakheet, S. M., Amin, T., Alia, A. G., et al. : F-18 FDG uptake in benign esophageal disease. Clin. Nucl. Med., 24 (12) ; 995-997, 1999.
pubmed

50) Yun, M., Yeh, D., Araujo, L. I., et al. : F18 FDG uptake in the large arteries : A new observation. Clin. Nucl. Med., 26 (4) ; 314-319, 2001.
pubmed

51) Meller, J., Strutz, F., Siefker, U., et al. : Early diagnosis and follow-up of aortitis with [(18) F] FDG PET and MRI. Eur. J. Nucl. Med. Mol. Imaging., 30 (5) ; 730-736, 2003.
pubmed

52) Yun, M., Jang, S., Cucchiara, A., et al. : 18F FDG uptake in the large arteries : A correlation study with the atherogenic risk factors. Semin. Nucl. Med., 32 (1) ; 70-76, 2002.
pubmed

53) Lewis, P. J., Salama, A. : Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis. J. Nucl. Med., 35 (10) ; 1647-1649, 1994.
pubmed

54) Yamada, Y., Uchida, Y., Tatsumi, K., et al. : Fluorine-18-fluorodeoxyglucose and carbon-11-methionine evaluation of lymphadenopathy in sarcoidosis. J. Nucl. Med., 39 (7) ; 1160-1166, 1998.
pubmed

55) Rini, J. N., Leonidas, J. C., Tomas, M. B., et al. : 18F-FDG PET versus CT for evaluating the spleen during initial staging of lymphoma. J. Nucl. Med., 44 (7) ; 1072-1074, 2003.
pubmed

56) Nunez, R. F., Yeung, H. W., Macapinlac, H. : Increased F-18 FDG uptake in the stomach. Clin. Nucl. Med., 24 (4) ; 281-282, 1999.
pubmed

57) Kato, T., Komatsu, Y., Tsukamoto, E., et al. : Intense F-18 FDG accumulation in the stomach in a patient with Menetrier's disease. Clin. Nucl. Med., 27 (5) ; 376-377, 2002.

58) Kim, S., Chung, J. K., Kim, B. T., et al. : Relationship between Gastrointestinal F-18-fluorodeoxyglucose Accumulation and Gastrointestinal Symptoms in Whole-Body PET. Clin. Positron Imaging, 2 (5) ; 273-279, 1999.

59) Kresnik, E., Gallowitsch, H. J., Mikosch, P., et al. : (18) F-FDG positron emission tomography in the early diagnosis of enterocolitis : Preliminary results. Eur. J. Nucl. Med. Mol. Imaging., 29 (10) ; 1389-1392, 2002.

60) Tatlidil, R., Jadvar, H., Bading, J. R., et al. : Incidental colonic fluorodeoxyglucose uptake : Correlation with colonoscopic and histopathologic findings. Radiology, 224 ; 783-787, 2002.
pubmed

61) Yasuda, S., Fujii, H., Nakahara, T., et al. : 18F-FDG PET detection of colonic adenomas. J. Nucl. Med., 42 (7) ; 989-992, 2001.
pubmed

62) Torizuka, T., Nobezawa, S., Kanno, T., et al. : Ovarian cancer recurrence : Role of whole-body positron emission tomography using 2- [fluorine-18] -fluoro-2-deoxy-D-glucose. Eur. J. Nucl. Med. Mol. Imaging, 29 ; 797-803, 2002.
pubmed

63) Chander, S., Meltzer, C. C., McCook, B. M. : Physiologic uterine uptake of FDG during menstruation demonstrated with serial combined positron emission tomography and computed tomography. Clin. Nucl. Med., 27 (1) ; 22-24, 2002.
pubmed

64) Chander, S., Ergun, E. L., Chugani, H. T., et al. : High 2-deoxy-2- [18F] fluoro-D-glucose accumulation in a case of retroperitoneal fibrosis following resection of carcinoid tumor. Mol. Imaging Biol., 4 (5) ; 363-368, 2002.

65) Roivainen, A., Parkkola, R., Yli-Kerttula, T., et al. : Use of positron emission tomography with methyl-11C-choline and 2-18F-fluoro-2-deoxy-D-glucose in comparison with magnetic resonance imaging for the assessment of inflammatory proliferation of synovium. Arthritis Rheum., 48 (11) ; 3077-3084, 2003.
pubmed

66) Yasuda, S., Shohtsu, A., Ide, M., et al. : F-18 FDG accumulation in inflamed joints. Clin. Nucl. Med., 21 (9) ; 740, 1996.
pubmed

67) Zhuang, H., Alavi, A. : 18-fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammation. Semin. Nucl. Med., 32 (1) ; 47-59, 2002.
pubmed

68) Bleeker-Rovers, C. P., De Kleijn, E. M., Corstens, F. H., et al. : Clinical value of FDG PET in patients with fever of unknown origin and patients suspected of focal infection or inflammation. Eur. J. Nucl. Med. Mol. Imaging. 31 (1) ; 29-27, 2004.
pubmed

P.59 掲載の参考文献

69) Yasuda, S., Ide, M., Fujii, H., et al. : Application of positron emission tomography imaging to cancer screening. Br. J. Cancer, 83 (12) ; 1607-1611, 2000.
pubmed

70) Chen, Y. K., Kao, C. H., Liao, A. C., et al. : Colorectal cancer screening in asymptomatic adults : The role of FDG PET scan. Anticancer Res., 23 (5b) ; 4357-4361, 2003.
pubmed

71) 井出満 : クリニカルPET-FDGの臨床応用 PETによる成人病検診 : 癌検診におけるFDG-PETの意義. 画像診断, 23 (10) ; 1190-1197, 2003.

72) Hustinx, R., Benard, F., Alavi, A. : Whole-body FDG-PET imaging in the management of patients with cancer. Semin. Nucl. Med., 32 (1) ; 35-46, 2002.
pubmed

73) Hicks, R. J., Kalff, V., MacManus, M. P., et al. : (18) F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer. J. Nucl. Med., 42 (11) ; 1596-1604, 2001.
pubmed

74) Kamel, E. M., Zwahlen, D., Wyss, M. T., et al. : Whole-Body (18) F-FDG PET Improves the Management of Patients with Small Cell Lung Cancer. J. Nucl. Med., 44 (12) ; 1911-1917, 2003.
pubmed

75) Kantorova, I., Lipska, L., Belohlavek, O., et al. : Routine (18) F-FDG PET preoperative staging of colorectal cancer : Comparison with conventional staging and its impact on treatment decision making. J. Nucl. Med., 44 (11) ; 1784-1788, 2003.
pubmed

76) Goerres, G. W., Schmid, D. T., Gratz, K. W., et al. : Impact of whole body positron emission tomography on initial staging and therapy in patients with squamous cell carcinoma of the oral cavity. Oral Oncol., 39 (6) ; 547-551, 2003.
pubmed

77) Belhocine, T., Thille, A., Fridman, V., et al. : Contribution of whole-body 18F-FDG PET imaging in the management of cervical cancer. Gynecol. Oncol., 87 (1) ; 90-97, 2002.
pubmed

78) Dizendorf, E. V., Baumert, B. G., von Schulthess, G. K., et al. : Impact of whole-body 18F-FDG PET on staging and managing patients for radiation therapy. J. Nucl. Med., 44 (1) ; 24-29, 2003.
pubmed

79) Verboom, P., van Tinteren, H., Hoekstra, O. S., Smit, E. F., et al. : Cost-effectiveness of FDG-PET in staging non-small cell lung cancer : The PLUS study. Eur. J. Nucl. Med. Mol. Imaging, 30 (11) ; 1444-1449, 2003.
pubmed

推薦の詞

P.78 掲載の参考文献

1) Fukuyama, H., Ogawa, M., Yamauchi, H., et al. : Altered cerebral energy metabolism in Alzheimer's disease. J. Nucl. Med., 35 (1) ; 1-6, 1994.
pubmed

2) Yoshida, T., Kuwabara, Y., Ichiya, Y., et al. : Cerebral muscarinic acetylcholinergic receptor measurement in Alzheimer's disease patients on 11C-N-methyl-4-piperidyl benzilate : Comparison with cerebral blood flow and cerebral glucose metabolism. Ann. Nucl. Med., 12 (1) ; 35-42, 1998.
pubmed

3) Bohnen, N. I. Neurologic applications. In : Wahl, R. L., Wagner, H. N. Jr, Morgan, R. H. et al. eds. : Principles and practice of positron emission tomography. Philadelphia : Lippincot Wiliams & Wilkins ; 276-297, 2002.

4) Newberg, A. B., Alavi, A., Berlin, J., et al. : Ipsilateral and contralateral thalamic hypometabolism as a predictor of outcome after temporal lobectomy for seizures. J. Nucl. Med., 41 (12) ; 1964-1968, 2000.
pubmed

5) 石井一成著, 西村恒彦編集 : FDG-PETによる痴呆 : 脳腫瘍の診断-最新脳SPECT/PETの臨床. メジカルビュー社, 東京 ; 130-139, 2002.

6) Acton, P. D., Friston, K. J. : Statistical parametric mapping in functional neuroimaging : Beyond PET and fMRI activation studies. Eur. J. Nucl. Med., 25 (7) ; 663-667, 1998.
pubmed

7) Minoshima, S., Frey, K. A., Koeppe, R. A., et al. : A diagnostic approach in Alzheimer's disease using three-dimrnsional stereotactic surface projections of fluorine-18-FDG PET. J. Nucl. Med., 36 (7) ; 1238-1248, 1995.

8) Minoshima, S., Giordani, B., Berent, S., et al. : Metabolic reduction in the posterior cingulated cortex in very early Alzheimer's disease. Ann. Neurol., 42 ; 85-94, 1997.
pubmed

9) Fulham, M. J., Central nervous system. In : Wahl, R. L., Wagner, H. N. Jr, Morgan, R. H. et al. eds. : Principles and practice of positron emission tomography. Philadelphia : Lippincot Williams & Wilkins, 137-156, 2002.

10) Gambhir, S. S., Czernin, J., Schwimmer, J., et al. : A tabulated summary of the FDG PET literature. J. Nucl. Med., 42 ; 32S-34S, 2001.

序

P.90 掲載の参考文献

1) Shreve, P. D. and Bui, C. D. Normal variants in FDG PET imaging. In : Wahl, R. L., Wagner, H. N. Jr, Morgan, R. H. et al. eds. : Principles and practice of positron emission tomography. Philadelphia : Lippincot Wlliams & Wilkins, 111-136, 2002.

2) Macapinlac, H. A. Head, neck, and thyroid. In : Wahl, R. L., Wagner, H. N. Jr, Morgan, R. H. et al. eds. : Principles and practice of positron emission tomography. Philadelphia : Lippincot Williams & Wilkins, 157-165, 2002.

3) Stahl, A., Dzewas, B., Schwaiger, M., et al. : Excretion of FDG into saliva and its significance for PET imaging. Nuklearmedizin, 41 (5) ; 214-216, 2002.
pubmed

4) Hany, T. F., Gharehpapagh, E., Kamel, E. M., et al. : Brown adipose tissue : A factor to consider in symmetrical tracer uptake in the neck and upper chest region. Eur. J. Nucl. Med. Mol. Imaging, 29 (10) ; 1393-1398, 2002.
pubmed

5) Keyes, J. W. Jr, Harkness, B. A., Greven, K. M., et al. : Salivery gland tumors : Pretherapy evaluation with PET. Radiology, 192 (1) ; 99-102, 1994.

6) Okamura, T., Kawabe, J., Koyama, K., et al. : Fluorine-18 fluorodeoxyglucose positron emission tomography imaging of parotid mass lesions. Acta Otolaryngol. Suppl., 538 ; 209-213, 1998.
pubmed

7) Matsuda, M., Sakamoto, H., Okamura, T., et al. : Positron emission tomographic imaging of pleomorphic adenoma in the parotid gland. Acta Otolaryngol. Suppl., 538 ; 214-220, 1998.
pubmed

8) Horiuchi, M., Yasuda, S., Shotsu, A., et al. : Four cases of Warthin's tumor of the parotid gland detected with FDG PET. Ann. Nucl. Med., 12 (1) ; 47-50, 1998.

9) Nowak, B. Di., Martino, E., Janicke, S., et al. : Diagnostic evaluation of malignant head and neck cancer by F-18-FDG PET compared to CT/MRI. Nuklearmedizin, 38 (8) ; 312-318, 1999.

10) Bui, C. D., Ching, A. S., Carlos, R. C., et al. : Diagnostic accuracy of 2- [fluorine-18] fluoro-2-deoxy-D-glucose positron emission tomography imaging in nonsquamous tumors of the head and neck. Invest Radiol., 38 (9) ; 593-601, 2003.
pubmed

11) Gambhir, S. S., Czernin, J., Schwimmer, J., et al. : A tabulated summary of the FDG PET literature. J. Nucl. Med., 42 ; 21S-25S, 2001.

12) Kitagawa, Y., Nishizawa, S., Sano, K., et al. : Whole-body (18) F-fluorodeoxyglucose positron emission tomography in patients with head and neck cancer. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod., 93 (2) ; 202-207, 2002.
pubmed

13) Johansen, J., Eigtved, A., Buchwald, C., et al. : Implication of 18F-fluoro-2-deoxy-D-glucose positron emission tomography on management of carcinoma of unknown primary in the head and neck : A Danish cohort study. Laryngoscope, 112 (11) ; 2009-2014, 2002.
pubmed

14) (社) 日本アイソトープ協会医学薬学部サイクロトロン核医学利用専門委員会FDG-PETワーキンググループ鳥塚莞爾 : 公表された文献によるFDG-PET検査の臨床的有用性の評価に関する調査報告. 核医学, 38 ; 363-372, 2001.

目次

P.96 掲載の参考文献

1) Kang, K. W., Kim, S. K., Kang, H. S., et al : Prevalence and risk of cancer of focal thyroid incidentaloma identified by 18F-fluorodeoxyglucose positron emission tomography for metastasis evaluation and cancer screening in healthy subjects. J. Clin. Endocrinol. Metab., 88 (9) ; 4100-4104, 2003.
pubmed

2) Van den Bruel, A., Maes, A., De Potter, T., et al. : Clinical relevance of thyroid fluorodeoxyglucose-whole body positron emission tomography incidentaloma. J. Clin. Endocrinol. Metab., 87 (4) ; 1517-1520, 2002.
pubmed

3) Cohen, M. S., Arslan, N., Dehdashti, F., et al. : Risk of malignancy in thyroid incidentalomas identified by fluorodeoxyglucose-positron emission tomography. Surgery, 130 (6) ; 941-946, 2001.
pubmed

4) Yasuda, S., Shohtsu, A., Ide, M., et al. : Chronic thyroiditis : Diffuse uptake of FDG at PET. Radiology, 207 (3) ; 775-778, 1998.
pubmed

5) Bloom, A. D., Adler, L. P., Shuck, J. M. : Determination of malignancy of thyroid nodules with positron emission tomography. Surgery, 114 (4) ; 728-734, 1993.
pubmed

6) Sasaki, M., Ichiya, Y., Kuwabara, Y., et al. : An evaluation of FDG-PET in the detection and differentiation of thyroid tumours. Nucl. Med. Commun., 18 (10) ; 957-963, 1997.
pubmed

7) Uematsu, H., Sadato, N., Ohtsubo, T., et al. : Fluorine-18-fluorodeoxyglucose PET versus thallium-201 scintigraphy evaluation of thyroid tumors. J. Nucl. Med., 39 (3) ; 453-459, 1998.
pubmed

8) Kresnik, E., Gallowitsch, H. J., Mikosch, P., et al. : Fluorine-18-fluorodeoxyglucose positron emission tomography in the preoperative assessment of thyroid nodules in an endemic goiter area. Surgery, 133 (3) ; 294-299, 2003.

9) Gianoukakis, A. G., Karam, M., Cheema, A., et al. : Autonomous thyroid nodules visualized by positron emission tomography with 18F-fluorodeoxyglucose : A case report and review of the literature. Thyroid, 13 (4) ; 395-399, 2003.
pubmed

10) Schmid, D. T., Kneifel, S., Stoeckli, S. J., et al. : Increased 18F-FDG uptake mimicking thyroid cancer in a patient with Hashimoto's thyroiditis. Eur. Radiol., 13 (9) ; 2119-2121, 2003.

11) Boerner, A. R., Voth, E., Theissen, P., et al. : Glucose metabolism of the thyroid in Graves' disease measured by F-18-fluoro-deoxyglucose positron emission tomography. Thyroid, 8 (9) ; 765-772, 1998.
pubmed

12) Lowe, V. J., Mullan, B. P., Hay, I. D., et al. : 18F-FDG PET of patients with Hurthle cell carcinoma. J. Nucl. Med., 44 (9) ; 1402-1406, 2003.
pubmed

13) Brandt-Mainz, K., Muller, S. P., Gorges, R., et al. : The value of fluorine-18 fluorodeoxyglucose PET in patients with medullary thyroid cancer. Eur. J. Nucl. Med., 27 (5) ; 490-496, 2000.
pubmed

14) Larson, S. M., Robbins, R. : Positron emission tomography in thyroid cancer management. Semin. Roentgenol., 37 (2) ; 169-174, 2002.
pubmed

15) McDougall, I. R., Davidson, J., Segall, G. M. : Positron emission tomography of the thyroid, with an emphasis on thyroid cancer. Nucl. Med. Commun., 22 (5) ; 485-492, 2001.
pubmed

16) Schonberger, J., Ruschoff, J., Grimm, D., et al. : Glucose transporter 1 gene expression is related to thyroid neoplasms with an unfavorable prognosis : An immunohistochemical study. Thyroid., 12 (9) ; 747-754, 2002.
pubmed

17) Feine, U., Lietzenmayer, R., Hanke, J. P., et al. : Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J. Nucl. Med., 37 (9) ; 1468-1472, 1996.
pubmed

18) Grunwald, F., Kalicke, T., Feine, U., et al. : Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer : Results of a multicentre study. Eur. J. Nucl. Med., 26 (12) ; 1547-1552, 1999.
pubmed

19) Shiga, T., Tsukamoto, E., Nakada, K., et al. : Comparison of (18) F-FDG, (131) I-Na, and (201) Tl in diagnosis of recurrent or metastatic thyroid carcinoma. J. Nucl. Med., 42 (3) ; 414-419, 2001.
pubmed

20) Schluter, B., Bohuslavizki, K. H., Beyer, W., et al. : Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan. J. Nucl. Med., 42 (1) ; 71-76, 2001.
pubmed

21) Helal, B. O., Merlet, P., Toubert, M. E., et al. : Clinical impact of (18) F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative (131) I scanning results after therapy. J. Nucl. Med., 42 (10) ; 1464-1469, 2001.
pubmed

22) Khan, N., Oriuchi, N., Higuchi, T., et al. : PET in the follow-up of differentiated thyroid cancer. Br. J. Radiol., 76 (910) ; 690-695, 2003.
pubmed

23) Chen, Y. K., Liu, F. Y., Yen, R. F., et al. : Compare FDG-PET and Tc-99m tetrofosmin SPECT to detect metastatic thyroid carcinoma. Acad. Radiol., 10 (8) ; 835-839, 2003.
pubmed

24) Petrich, T., Borner, A. R., Otto, D., et al. : Influence of rhTSH on [(18) F] fluorodeoxyglucose uptake by differentiated thyroid carcinoma. Eur. J. Nucl. Med. Mol. Imaging, 29 (5) ; 641-647, 2002.
pubmed

25) Wang, W., Larson, S. M., Tuttle, R. M., et al. : Resistance of [18f]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. Thyroid, 11 (12) ; 1169-1175, 2001.
pubmed

26) Szakall, S. Jr., Esik, O., Bajzik, G., et al. : 18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma. J. Nucl. Med., 43 (1) ; 66-71, 2002.
pubmed

第1章総論

P.108 掲載の参考文献

1) Gould, M. K., Maclean, C. C., Kuschner, W. G., et al. : Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions : A meta-analysis. JAMA, 21, 285 (7) ; 914-924, 2001.

2) Marom, E. M., Sarvis, S., Herndon, J. E. 2nd, et al. : T1 lung cancers : Sensitivity of diagnosis with fluorodeoxyglucose PET. Radiology, 223 (2) ; 453-459, 2002.
pubmed

3) Menda, Y., Bushnell, D. L., Madsen, M. T., et al. : Evaluation of various corrections to the standardized uptake value for diagnosis of pulmonary malignancy. Nucl. Med. Commun., 22 (10) ; 1077-1081, 2001.

4) Nehmeh, S. A., Erdi, Y. E, Ling, C. C., et al. : Effect of respiratory gating on reducing lung motion artifacts in PET imaging of lung cancer. Med. Phys., 29 (3) ; 366-371, 2002.
pubmed

5) Matthies, A., Hickeson, M., Cuchiara, A., et al. : Dual time point 18F-FDG PET for the evaluation of pulmonary nodules. J. Nucl. Med., 43 (7) ; 871-875, 2002.
pubmed

6) Kubota, K., Itoh, M., Ozaki, K., et al. : Advantage of delayed whole-body FDG-PET imaging for tumour detection. Eur. J. Nucl. Med., 28 (6) ; 696-703, 2001.
pubmed

7) Demura, Y., Tsuchida, T., Ishizaki, T., et al. : 18F-FDG accumulation with PET for differentiation between benign and malignant lesions in the thorax. J. Nucl. Med., 44 (4) ; 540-548, 2003.
pubmed

8) 陣之内正史, 田邉博昭 : FDG-PETのピットフォール-delayed scanの有用性を中心に. 臨床核医学, 36 (4) ; 53-56, 2003.

9) Higashi, K., Ueda, Y., Ayabe, K., Sakurai, A., et al. : FDG PET in the evaluation of the aggressiveness of pulmonary adenocarcinoma : Correlation with histopathological features. Nucl. Med. Commun., 21 (8) ; 707-714, 2000.
pubmed

10) Wong, C. Y., Nunez, R., Bohdiewicz, P., et al. : Patterns of abnormal FDG uptake by various histological types of non-small cell lung cancer at initial staging by PET. Eur. J. Nucl. Med., 28 (11) ; 1702-1705, 2001.
pubmed

11) Tateishi, U., Nishihara, H., Tsukamoto, E., et al. : Lung tumors evaluated with FDG-PET and dynamic CT : The relationship between vascular density and glucose metabolism. J. Comput. Assist. Tomogr., 26 (2) ; 185-190, 2002.
pubmed

12) Vesselle, H., Schmidt, R. A., Pugsley, J. M., et al. : Lung cancer proliferation correlates with [F18] fluorodeoxyglucose uptake by positron emission tomography. Clin. Cancer Res., 6 (10) ; 3837-3844, 2000.
pubmed

13) Brown, R. S., Leung, J. Y., Kison, P. V., et al. : Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer. J. Nucl. Med., 40 (4) ; 556-565, 1999.
pubmed

14) Higashi, K., Ueda, Y., Sakurai, A., et al. : Correlation of Glut-1 glucose transporter expression with. Eur. J. Nucl. Med., 27 (12) ; 1778-1785, 2000.

15) Yap, C. S., Schiepers, C., Fishbein, M. C., et al. : FDG-PET imaging in lung cancer : How sensitive is it for bronchioloalveolar carcinoma? Eur. J, Nucl. Med. Mol. Imaging, 29 (9) ; 1166-1173, 2002.
pubmed

16) Higashi, K., Ueda, Y., Seki, H., et al. : Fluorine-18-FDG PET imaging is negative in bronchioloaiveoiar lung carcinoma. J. Nucl. Med., 39 (6) ; 1016-1O20, 1998.
pubmed

17) Hicks, R. J., Kalff, V., MacManus, M. P., et al. : (18) F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer. J. Nucl. Med., 42 (11) ; 1596-1604, 2001.
pubmed

18) Seltzer, M. A., Yap, C. S., Silverman, D. H., et al. : The impact of PET on the management of lung cancer : The referring physician's perspective. J. Nucl. Med., 43 (6) ; 752-756, 2002.
pubmed

19) Gould, M. K., Kuschner, W. G., Rydzak, C. E., et al. : Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer : A meta-analysis. Ann. Intern. Med., 2 ; 139 (11) ; 879-892, 2003.
pubmed

20) Konishi, J., Yamazaki, K., Tsukamoto, E., et al. : Mediastinal Lymph Node Staging by FDG-PET in Patients with Non-Small Cell Lung Cancer : Analysis of False-Positive FDG-PET Findings. Respiration, 70 (5) ; 500-506, 2003.
pubmed

21) Kwan, A., Seltzer, M., Czernin, J., et al. : Characterization of hilar lymph node by 18F-fluoro-2-deoxyglucose positron emission tomography in healthy subjects. Anticancer Res., 21 (1B) ; 701-706, 2001.
pubmed

22) Kamel, E. M., Zwahlen, D., Wyss, M. T., et al. : Whole-Body (18) F-FDG PET Improves the Management of Patients with Small Cell Lung Cancer. J. Nucl. Med., 44 (12) ; 1911-1917, 2003.
pubmed

23) Hsia, T. C., Shen, Y. Y., Yen, R. F., et al. : Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diophosphate bone scan to detect bone metastases in patients with non-small cell lung cancer. Neoplasma, 49 (4) ; 267-271, 2002.
pubmed

第2章各論

P.114 掲載の参考文献

1) Alibazoglu, H., Alibazoglu, B., Hollinger, E. F., et al. : Normal thymic uptake of 2-deoxy-2 [F-18] fiuoro-D-glucose. Clin. Nucl. Med., 24 (8) ; 597-600, 1999.

2) Nakahara, T., Fujii, H., Ide, M., et al. : FDG uptake in the morphologically normal thymus : Comparison of FDG positron emission tomography and CT. Br. J. Radiol., 74 (885) ; 821-824, 2001.
pubmed

3) Wittram, C., Fischman, A. J., Mark, E., et al. : Thymic enlargement and FDG uptake in three patients : CT and FDG positron emission tomography correlated with pathoiogy. AJR Am. J. Roentgenol., 180 (2) ; 519-522, 2003.
pubmed

4) Liu, R. S., Yeh, S. H., Huang, M. H., et al. : Use of fluorine-18 fluorodeoxyglucose positron emission tomography in the detection of thymoma : A preliminary report. Eur. J. Nucl. Med., 22 (12) ; 1402-1407, 1995.
pubmed

5) Kubota, K., Yamada, S., Kondo, T., et al. : PET imaging of primary mediastinal tumours. Br. J. Cancer, 73 (7) ; 882- 886, 1996.

6) Sasaki, M., Kuwabara, Y., Ichiya, Y., et al. : Differential diagnosis of thymic tumors using a combination of 11C-methionine PET and FDG PET. J. Nucl. Med., 40 (10) ; 1595-1601, 1999.

7) Hsu, C. H., Lee, C. M., Wang, F. C., et al. : Neurofibroma with increased uptake of [F-18] -fluoro-2 deoxy-D-glucose interpreted as a metastatic lesion. Ann. Nucl. Med., 17 (7) ; 609-611, 2003.
pubmed

8) Kang, W. J., Chung, J. K., So, Y., et al. : Differentiation of mediastinal FDG uptake observed in patients with non-thoracic tumours. Eur. J. Nucl. Med. Mol. Imaging, 31 (2) ; 202-207, 2004.
pubmed

略語一覧

P.124 掲載の参考文献

1) Rose, C., Dose. J., Avril, N. : Positron emission tomography for the diagnosis of breast cancer. Nucl. Med. Commun., 23 (7) ; 613-618, 2002.
pubmed

2) Wahl, R. L. : Current status of PET in breast cancer imaging, staging, and therapy. Semin. Roentgenol., 36 (3) ; 250-260, 2001.
pubmed

3) Vranjesevic, D., Schiepers, C., Silverman, D. H., et al. : Relationship between 18F-FDG uptake and breast density in women with normal breast tissue. Relationship between 18F-FDG uptake and breast density in women with normal breast tissue. J. Nucl. Med., 44 (8) ; 1238-1242, 2003.

4) Walter, C., Scheidhauer, K., Scharl, A., et al. : Clinical and diagnostic value of preoperative MR mammography and FDG-PET in suspicious breast lesions. Eur. Radiol., 13 (7) ; 1651-1656, 2003.
pubmed

5) Samson, D. J., Flamm, C. R., Pisano, E. D., et al. : Should FDG PET be used to decide whether a patient with an abnormal mammogram or breast finding at physical examination should undergo biopsy? Acad. Radiol., 9 (7) ; 773-783, 2002.
pubmed

6) Bakheet, S. M., Powe, J., Kandil, A., et al. : F-18 FDG uptake in breast infection and inflammation. Clin. Nucl. Med., 25 (2) ; 100-103, 2000.
pubmed

7) 長町茂樹, 陣之内正史, 田邉博昭, 他 : FDG-PETのピットフォール : Delayed scanの有用性を中心に-乳腺. 臨床核医学, 37 (1) ; 3-5, 2004.
Medical*Online

8) Beaulieu, S., Kinahan, P., Tseng, J., et al. : SUV varies with time after injection in (18) F-FDG PET of breast cancer : Characterization and method to adjust for time differences. J. Nucl. Med., 44 (7) ; 1044-1050, 2003.
pubmed

9) Boerner, A. R., Weckesser, M., Herzog, H., et al. : Optimal scan time for fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer. Eur. J. Nucl, Med., 26 (3) ; 226-230, 1999.
pubmed

10) Zasadny, K. R., Tatsumi, M., Wahl, R. L. : FDG metabolism and uptake versus blood flow in women with untreated primary breast cancers. Eur. J. Nucl. Med. Mol. Imaging, 30 (2) ; 274-280, 2003.
pubmed

11) Buck, A., Schirrmeister, H., Kuhn, T., et al. : FDG uptake in breast cancer : Correlation with biological and clinical prognostic parameters. Eur. J. Nucl. Med. Mol. Imaging, 29 (10) ; 1317-1323, 2002.
pubmed

12) Mankoff, D. A., Dunnwald, L. K., Gralow, J. R., et al. : Blood flow and metabolism in locally advanced breast cancer : Relationship to response to therapy. J. Nucl. Med., 43 (4) ; 500-509, 2002.
pubmed

13) Avril, N., Menzel, M., Dose, J., et al. : Glucose metabolism of breast cancer assessed by 18F-FDG PET : Histologic and immunohistochemical tissue analysis. J. Nucl. Med., 42 (1) ; 9-16, 2001.
pubmed

14) Oshida, M., Uno, K., Suzuki, M., et al. : Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2-fluoro [18F] -D-glucose. Cancer, 82 (11) ; 2227-2234, 1998.
pubmed

15) Danforth, D. N. Jr., Aloj, L., Carrasquillo, J. A., et al. : The role of 18F-FDG-PET in the local/regional evaluation of women with breast cancer. Breast Cancer Res. Treat., 75 (2) ; 135-146, 2002.
pubmed

16) Barranger, E., Grahek, D., Antoine, M., et al. : Evaluation of fluorodeoxyglucose positron emission tomography in the detection of axillary lymph node metastases in patients with early-stage breast cancer. Ann. Surg. Oncol., 10 (6) ; 622-627, 2003.
pubmed

17) Guller, U., Nitzsche, E. U., Schirp, U., et al. : Selective axillary surgery in breast cancer patients based on positron emission tomography with 18F-fluoro-2-deoxy-D-glucose : Not yet! Breast Cancer Res. Treat., 71 (2) ; 171-173, 2002.
pubmed

18) Crippa, F., Agresti, R., Seregni, E. : Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer. J. Nucl. Med., 39 (1) ; 4-8, 1998.
pubmed

19) Yang, S. N., Liang, J. A., Lin, F. J., et al. : Comparing whole body (18) F-2-deoxygiucose positron emission tomography and technetium-99m methylene diphosphonate bone scan to detect bone metastases in patients with breast cancer. J. Cancer Res. Clin. Oncol., 128 (6) ; 325-328, 2002.

20) Ohta, M., Tokuda, Y., Suzuki, Y., et al. : Whole body PET for the evaluation of bony metastases in patients with breast cancer : Comparison with 99mTc-MDP bone scintigraphy. Nucl. Med. Commun., 22 (8) ; 875-879, 2001.
pubmed

21) Kao, C. H., Hsieh, J. F., Tsai, S. C., et al. : Comparison and discrepancy of 18F-2-deoxyglucose positron emission tomography and Tc-99m MDP bone scan to detect bone metastases. Anticancer Res., 20 (3B) ; 2189-2192, 2000.
pubmed

22) Dose, J., Bleckmann, C., Bachmann, S., et al. : Comparison of fluorodeoxyglucose positron emission tomography and "conventional diagnostic procedures" for the detection of distant metastases in breast cancer patients. Nucl. Med. Commun., 23 (9) ; 857-864, 2002.
pubmed

23) Yap, C. S., Seltzer, M. A., Schiepers, C. : Impact of whole-body 18F-FDG PET on staging and managing patients with breast cancer : The referring physician's perspective. J. Nucl. Med., 42 (9) ; 1334-1337, 2001.
pubmed

24) 宇野公一, 呉勁, 留森貴志, 他 : FDG-PETは乳癌診療体系を変えるか. 画像診断, 21 (9) ; 1003-1010, 2001.

25) Eubank, W. B., Mankoff, D. A., Vesselle, H. J., et al. : Detection of locoregional and distant recurrences in breast cancer patients by using FDG PET. Radiographics, 2 (1) ; 5-17, 2002.
pubmed

26) Goerres, G. W., Michel, S. C., Fehr, M. K., et al. : Follow-up of women with breast cancer : Comparison between MRI and FDG PET. Eur. Radiol., 13 (7) ; 1635-1644, 2003.
pubmed

27) Eubank, W. B., Mankoff, D. A., Takasugi, J., et al. : 18fluorodeoxyglucose positron emission tomography to detect mediastinal or internal mammary metastases in breast cancer. J. Clin, Oncol., 19 (15) ; 3516-3523, 2001.
pubmed

28) Siggelkow, W., Zimny, M., Faridi, A., et al. : The value of positron emission tomography in the follow-up for breast cancer. Anticancer Res., 23 (2C) ; 1859-1867, 2003.
pubmed

29) Gallowitsch, H. J., Kresnik, E., Gasser, J., et al. : F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma : A comparison to conventional imaging. Invest. Radiol., 38 (5) ; 250-256, 2003.
pubmed

30) Vranjesevic, D., Filmont, J. E., Meta, J., et al. : Whole-body (18) F-FDG PET and conventional imaging for predicting outcome in previously treated breast cancer patients. J. Nucl. Med., 43 (3) ; 325-329, 2002.
pubmed

31) Moon, D. H., Maddahi, J., Silverman, D. H., et al. : Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma. J. Nucl. Med., 39 (3) ; 431-435, 1998.
pubmed

索引

P.136 掲載の参考文献

1) Iwata, Y., Shiomi, S., Sasaki, N., et al. : Clinical usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose in the diagnosis of liver tumors. Ann. Nucl. Med., 14 (2) ; 121-126, 2000.
pubmed

2) Kubota, K., Itoh, M., Ozaki, K., et al. : Advantage of delayed whole-body FDG-PET imaging for tumour detection. Eur. J. Nucl. Med., 28 (6) ; 696-703, 2001.
pubmed

3) Koyama, K., Okamura, T., Kawabe, J., et al. : The usefulness of 18F-FDG PET images obtained 2 hours after intravenous injection in liver tumor. Ann. Nucl. Med., 16 (3) ; 169-176, 2002.
pubmed

4) Delbeke, D., Martin, W. H., Sandier, M. P., et al. : Evaluation of benign vs malignant hepatic lesions with positron emission tomography. Arch. Surg., 133 (5) ; 510-516, 1998.

5) Kurtaran, A., Becherer, A., Pfeffel, F., et al. : 18F-fluorodeoxyglucose (FDG) -PET features of focal nodular hyperplasia (FNH) of the liver. Liver, 20 (6) ; 487-490, 2000.
pubmed

6) Torizuka, T., Tamaki, N., Inokuma, T., et al. : In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J. Nucl. Med., 36 ; 1811-1817, 1995.

7) Trojan, J., Schroeder, O., Raedle, J., et al. : Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Am. J. Gastroenterol., 94 (11) ; 3314-3319, 1999.
pubmed

8) Kim, Y. J., Yun, M., Lee, W. J., et al. : Usefulness of 18F-FDG PET in intrahepatic cholangiocarcinoma. Eur. J. Nucl. Med. Mol. Imaging, 30 (11) ; 1467-1472, 2003.
pubmed

9) Fritscher-Ravens, A., Bohuslavizki, K. H., Broering, D. C., et al. : FDG PET in the diagnosis of hilar cholangiocarcinoma. Nucl. Med. Commun,, 22 (12) ; 1277-1285, 2001.
pubmed

10) Kluge, R., Schmidt, F., Caca, K., et al. : Positron emission tomography with [(18) F] fluoro-2-deoxy-D-glucose for diagnosis and staging of bile duct cancer. Hepatology, 33 (5) ; 1029-1035, 2001.
pubmed

11) Koh, T., Taniguchi, H., Yamaguchi, A., et al. : Differential diagnosis of gallbladder cancer using positron emission tomography with fluorine-18-labeled fluoro-deoxyglucose (FDG-PET). J. Surg. Oncol., 84 (2) ; 74-81, 2003.

12) Koh, T., Taniguchi, H., Kunishima, S., et al. : Possibility of Differential Diagnosis of Small Polypoid Lesions in the Gallbladder Using FDG-PET. Clin. Positron Imaging, 3 (5) ; 213-218, 2000.
pubmed

13) Kantorova, I., Lipska, L., Belohlavek, O., et al. : Routine (18) F-FDG PET preoperative staging of colorectal cancer : Comparison with conventional staging and its impact on treatment decision making. J. Nucl. Med., 44 (11) ; 1784-1788, 2003.
pubmed

14) Kinkel, K., Lu, Y., Both, M., et al. : Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET) : A meta-analysis. Radiology, 224 (3) ; 748-756, 2002.
pubmed

15) Wiesner, W., Engel, H., von Schulthess, G. K., et al. : FDG PET-negative liver metastases of a malignant melanoma and FDG PET-positive hurthle cell tumor of the thyroid. Eur. Radiol., 9 (5) ; 975-978, 1999.
pubmed

16) Hustinx, R., Paulus, P., Jacquet, N., et al. : Clinical evaluation of whole-body 18F-fluorodeoxyglucose positron emission tomography in the detection of liver metastases. Ann. Oncol., 9 (4) ; 397-401, 1998.
pubmed

17) 今本栄子, 内藤裕二, 口出将司, 他 : 手術不能転移性肝癌に対する動注化学療法におけるFDG-PETを用いた効果判定の検討. 癌と化学療法, 27 ; 1973-1976, 2000.
Medical*Online

著者紹介 / 施設紹介

P.144 掲載の参考文献

1) Zimny, M., Bares, R., Fass, J., et al. : Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma : A report of 106 cases. Eur. J. Nucl. Med., 24 (6) ; 678-682, 1997.
pubmed

2) Keogan, M. T., Tyler, D., Clark, L., et al. : Diagnosis of pancreatic carcinoma ; Role of FDG PET. Am. J. Roentgenol., 171 (6) ; 1565-1570, 1998.

3) Diederichs, C. G., Staib, L., Glatting, G., et al. : FDG PET ; Elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies. J. Nucl. Med., 39 (6) ; 1030-1033, 1998.
pubmed

4) Shreve, P. D. : Focal fluorine-18 fluorodeoxyglucose accumulation in inflammatory pancreatic disease. Eur. J. Nucl. Med., 25 (3) ; 259-264, 1998.
pubmed

5) Nakamoto, Y., Higashi, T., Sakahara, H. et al. : Delayed (18) F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas. Cancer, 89 (12) ; 2547-2554, 2000.
pubmed

6) Koyama, K., Okamura, T., Kawabe, J., et al. : Diagnostic usefulness of FDG PET for pancreatic mass lesions. Ann. Nucl. Med., 15 (3) ; 217-224, 2001.
pubmed

7) Sperti, C., Pasquali, C., Chierichetti, F., et al. : Value of 18-fluorodeoxyglucose positron emission tomography in the management of patients with cystic tumors of the pancreas. Ann. Surg., 234 (5) ; 675-680, 2001.
pubmed

8) Sperti, C., Pasquali, C., Chierichetti, F., et al. : 18-Fluorodeoxyglucose positron emission tomography in predicting survival of patients with pancreatic carcinoma. J. Gastrointest Surg., Dec ; 7 (8) ; 953-960, 2003.
pubmed

9) Nakata, B., Nishimura, S., Ishikawa, T., et al. : Prognostic predictive value of 18F-fluorodeoxyglucose positron emission tomography for patients with pancreatic cancer. Int. J. Oncol., 19 (1) ; 53-58, 2001.

10) Yoshioka, M., Sato, T., Furuya, T., et al. : Positron emission tomography with 2-deoxy-2- [(18) F] fluoro-d-glucose for diagnosis of intraductal papillary mucinous tumor of the pancreas with parenchymal invasion. J. Gastroenterol., 38 (12) ; 1189-1193, 2003.
pubmed

11) Nakamoto, Y., Higashi, T., Sakahara, H., et al. : Evaluation of pancreatic islet cell tumors by fluorine-18 fluorodeoxyglucose positron emission tomography : Comparison with other modalities. Clin. Nucl. Med., 25 (2) ; 115-119, 2000.
pubmed

12) Majhail, N. S., Urbain, J. L., Albani, J. M., et al. : F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma. J. Clin. Oncol., 21 (21) ; 3995-4000, 2003.
pubmed

13) Nakamoto, Y., Higashi, T., Sakahara, H., et al. : Contribution of PET in the detection of liver metastases from Pancreatic tumours. Clin. Radiol., 54 (4) ; 248-252, 1999.
pubmed

14) 陣之内正史, 田邉博昭 : FDG-PETのピットフォール : 膵-delayed scanの有用性. 臨床核医学, 36 (5) ; 66-68, 2003.
Medical*Online

15) Frohlich, A., Diederichs, C. G., Staib, L., et al. : Detection of liver metastases from pancreatic cancer using FDG PET. J. Nucl. Med., 40 (2) ; 250-255, 1999.

奥付

P.150 掲載の参考文献

1) Wahl, R. L. Esophagus. In : Wahl, R. L., Wagner, H. N. Jr, Morgan, R. H., et al. eds. : Principles and practice of positron emission tomography. Philadelphia : Lippincot Williams & Wilkins, 210-216, 2002.

2) Yoon, Y. C., Lee, K. S., Shim, Y. M., et al. : Metastasis to regional lymph nodes in patients with esophageal squamous cell carcinoma : CT versus FDG PET for presurgical detection prostective study. Radiology, 227 (3) ; 764-770, 2003.

3) Kato, H., Kuwano, H., Nakajima, M., et al. : Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma. Cancer, 94 ; 921-928, 2002.
pubmed

4) 新井清和, 加藤広行, 井上登美夫, 他 : 食道癌におけるFDG-PET検査の有用性と医療経済学的効果 : アンケート調査の集計結果などに基づいた検討. Radioisotopes, 52 ; 599-607, 2003.

5) (社) 日本アイソトープ協会医学薬学部サイクロトロン核医学利用専門委員会FDG-PETワーキンググループ鳥塚莞爾 : 公表された文献によるFDG-PET検査の臨床的有用性の評価に関する調査報告. 核医学, 38 ; 363-372, 2001.

はじめての方へ

個人／法人会員登録のご案内